908269-97-6

Basic information

• Product Name: 4-cyclopropylpyridin-2-aMine
• Synonyms: 4-cyclopropylpyridin-2-aMine;4-CYCLOPROPYLPYRIDIN-2-AMINE(WXC09168)
• CAS NO: 908269-97-6
• Molecular Formula: C₈H₁₀N₂
• Molecular Weight: 134.1784
• Mol File: 908269-97-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 266.6±28.0 °C(Predicted)
• Appearance: /
• Density: 1.188±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 7.54±0.11(Predicted)
• CAS DataBase Reference: 4-cyclopropylpyridin-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-cyclopropylpyridin-2-aMine(908269-97-6)
• EPA Substance Registry System: 4-cyclopropylpyridin-2-aMine(908269-97-6)

Safety Data

• Hazardous Substances Data: 908269-97-6(Hazardous Substances Data)

Upstream product

• 19798-80-2 2-Amino-4-chloropyridine 
• 411235-57-9 cyclopropylboronic acid 
• 84249-14-9 2-amino-4-bromopyridine 

Downstream Products

• 1419221-44-5 N-(4-cyclopropylpyridin-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1620677-27-1 (4-((4-cyclopropylpyridin-2-yl)carbamoyl)-3-fluorophenyl)boronic acid 
• 1411772-38-7 6-bromo-N-(4-cyclopropylpyridine-2-yl)-4-methylpyridine-2-amine 

Relevant articles and documents

PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g., respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).

USP7 INHIBITOR COMPOUNDS AND METHODS OF USE

2-Aminopyridine compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for modulating USP7, and for treating cancer and immune disorders such as inflammation mediated by USP7. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.